INT287268

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.16
First Reported 2009
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 5
Disease Relevance 2.74
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (ERBB2, ERBB3) plasma membrane (ERBB2, ERBB3) nucleus (ERBB2, ERBB3)
cell proliferation (ERBB2) extracellular space (ERBB3) extracellular region (ERBB3)
Anatomy Link Frequency
arm 2
ERBB2 (Homo sapiens)
ERBB3 (Homo sapiens)
Pain Link Frequency Relevance Heat
palliative 3 32.16 Quite Low
imagery 50 27.04 Quite Low
Central nervous system 21 5.00 Very Low Very Low Very Low
Kinase C 18 5.00 Very Low Very Low Very Low
Inflammation 5 5.00 Very Low Very Low Very Low
Pain 4 5.00 Very Low Very Low Very Low
cva 3 5.00 Very Low Very Low Very Low
anesthesia 2 5.00 Very Low Very Low Very Low
alcohol 2 5.00 Very Low Very Low Very Low
Bioavailability 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Solid Tumor 9 98.92 Very High Very High Very High
Hyperplasia 8 91.72 High High
Cancer 283 89.68 High High
Disease 165 89.40 High High
Toxicity 35 86.48 High High
Metastasis 46 83.32 Quite High
Advanced Or Metastatic Breast Cancer 30 81.88 Quite High
Ovarian Cancer 66 80.24 Quite High
Carcinoma 7 79.64 Quite High
Breast Cancer 320 79.52 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The HER2/HER3 heterodimer has been shown to function as an oncogenic unit, with HER2 requiring dimerization with HER3 to drive proliferation [64].
HER2 Binding (dimerization) of HER3
1) Confidence 0.16 Published 2009 Journal Target Oncol Section Body Doc Link PMC2778706 Disease Relevance 0.72 Pain Relevance 0
ErbB2, whilst having no exogenous ligand, is the preferred partner for heterodimerization with ErbB1, ErbB3 and ErbB4 as it amplifies the mitogenic signal with potent growth and survival effects.
ErbB2 Binding (heterodimerization) of ErbB3
2) Confidence 0.14 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004582 Disease Relevance 0.27 Pain Relevance 0
Pertuzumab has been shown to bind to the dimerization arm of HER2, blocking HER2/HER3 heterodimerization and attenuating growth of solid tumors in model systems [133].
HER2 Binding (heterodimerization) of HER3 in arm associated with solid tumor
3) Confidence 0.12 Published 2010 Journal Current Genomics Section Body Doc Link PMC2878980 Disease Relevance 0.57 Pain Relevance 0
Pertuzumab has been shown to bind to the dimerization arm of HER2, blocking HER2/HER3 heterodimerization and attenuating growth of solid tumors in model systems [133].
HER2 Binding (heterodimerization) of HER3 in arm associated with solid tumor
4) Confidence 0.12 Published 2010 Journal Current Genomics Section Body Doc Link PMC2878980 Disease Relevance 0.57 Pain Relevance 0
Pertuzumab is a monoclonal antibody that inhibits dimerization of ERBB2 with EGFR, ERBB3, and ERBB4.
ERBB2 Binding (dimerization) of ERBB3
5) Confidence 0.07 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2814233 Disease Relevance 0.60 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox